Anti-tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards
Cancer Commun (Lond)
.
2024 Nov 20.
doi: 10.1002/cac2.12630.
Online ahead of print.
Authors
Ling Tang
1
,
Yuanyuan Song
2
,
Hong Zhang
2
,
Ruimin Hao
2
,
Xin Tong
2
,
Xing Ai
2
,
Jun Ma
3
,
Zhimin Yang
4
Affiliations
1
Office of Clinical Trial Management, Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China.
2
Office of Clinical Evaluation 1, Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China.
3
Harbin Institute of Hematology and Oncology, Harbin, Heilongjiang, P. R. China.
4
Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China.
PMID:
39563620
DOI:
10.1002/cac2.12630
No abstract available
Publication types
Editorial